Pmv Pharmaceuticals Inc Asset Resilience Ratio
Pmv Pharmaceuticals Inc asset resilience ratio. Pmv Pharmaceuticals Inc (PMVP) has an Asset Resilience Ratio of 81.59% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PMVP cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Pmv Pharmaceuticals Inc (2018–2025)
Asset resilience ratio of Pmv Pharmaceuticals Inc from 2018 to 2025. This chart shows how Pmv Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read PMVP current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Pmv Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see PMVP total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $66.96 Million | 81.59% |
| Total Liquid Assets | $66.96 Million | 81.59% |
Asset Resilience Insights
- Very High Liquidity: Pmv Pharmaceuticals Inc maintains exceptional liquid asset reserves at 81.59% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Pmv Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Pmv Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Pmv Pharmaceuticals Inc Asset Resilience Ratio by Year (2018–2025)
Pmv Pharmaceuticals Inc asset resilience ratio by year from 2018 to 2025. The table below shows the annual Asset Resilience Ratio data for Pmv Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 64.31% | $74.96 Million | $116.56 Million | -2.91pp |
| 2024-12-31 | 67.22% | $128.58 Million | $191.29 Million | +1.64pp |
| 2023-12-31 | 65.58% | $165.35 Million | $252.15 Million | +16.46pp |
| 2022-12-31 | 49.11% | $132.76 Million | $270.31 Million | +11.51pp |
| 2021-12-31 | 37.61% | $124.70 Million | $331.57 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $365.53 Million | -- |
| 2019-12-31 | 27.38% | $28.21 Million | $103.03 Million | -22.42pp |
| 2018-12-31 | 49.80% | $31.60 Million | $63.46 Million | -- |
About Pmv Pharmaceuticals Inc
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. an… Read more